ADMA Biologics, Inc. (ADMA) has a MoatMap StockRank of 38/100 based on Quality (70/100), Value (38/100), and Momentum (17/100) factor scores. The current signal is HOLD. ADMA Biologics is a high-growth, vertically integrated specialty biologics company that owns scarce, FDA-approved manufacturing facilities for plasma-derived therapies. This physical and regulatory manufacturing bottleneck creates an immense moat, allowing ADMA to command exceptional pricing power for its proprietary immunoglobulins (ASCENIV and BIVIGAM). As they scale utilization of their existing footprint, operating leverage is driving explosive free cash flow growth, making this a classic high-ROIC compounder hiding in plain sight.
ADMA Biologics, Inc. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived therapeutics for immunocompromised patients. The company operates a vertically integrated business model, from plasma collection centers to manufacturing facilities, providing a secure supply chain and quality control for its essential products. This integration and focus on niche patient populations contribute to its competitive moat.
| Price | $7.76 |
| Market Cap | $1.8B |
| P/E (TTM) | 11.74 |
| P/E (Forward) | 7.55 |
| Price/Book | 4.75 |
| Return on Equity | 43.3% |
| Return on Invested Capital | 34.2% |
| Debt/Equity | 110.67 |
| Gross Margin | 61.3% |
| Operating Margin | -123.4% |
| Revenue Growth | 15.9% |
| Free Cash Flow | $58M |
ADMA Biologics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).